These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9885455)

  • 1. The preliminary economic evaluation of health technologies for the prioritization of health technology assessments. A discussion.
    Harper G; Townsend J; Buxton M
    Int J Technol Assess Health Care; 1998; 14(4):652-62. PubMed ID: 9885455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of health technology: economic issues for health policy and policy issues for economic appraisal.
    Drummond M
    Soc Sci Med; 1994 Jun; 38(12):1593-600. PubMed ID: 8047916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in the cross-national assessment of health technology.
    Drummond MF; Bloom BS; Carrin G; Hillman AL; Hutchings HC; Knill-Jones RP; de Pouvourville G; Torfs K
    Int J Technol Assess Health Care; 1992; 8(4):671-82. PubMed ID: 1464487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of technology on health care costs.
    Cotterill PG
    Profile Med Pract; 1980; ():107-21. PubMed ID: 10309443
    [No Abstract]   [Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology assessment in Catalonia: integrating economic appraisal.
    Granados A; Borràs JM
    Soc Sci Med; 1994 Jun; 38(12):1643-6. PubMed ID: 8047922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
    Miners AH; Garau M; Fidan D; Fischer AJ
    BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New technologies, critical care, and economic realities.
    Sibbald WJ; Eberhard JA; Inman KJ; Sprung CL
    Crit Care Med; 1993 Nov; 21(11):1777-80. PubMed ID: 8222697
    [No Abstract]   [Full Text] [Related]  

  • 9. A PROCESS OF PRIORITIZING TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN KAZAKHSTAN.
    Kosherbayeva L; Hailey D; Kurakbaev K; Tabarov A; Kumar A; Gutzskaya G; Stepkina E
    Int J Technol Assess Health Care; 2016 Jan; 32(3):147-51. PubMed ID: 27502426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allocating resources.
    Drummond MF
    Int J Technol Assess Health Care; 1990; 6(1):77-92. PubMed ID: 2113892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iterative use of economic evaluation as part of the process of health technology assessment.
    Sculpher M; Drummond M; Buxton M
    J Health Serv Res Policy; 1997 Jan; 2(1):26-30. PubMed ID: 10180650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation and the rational diffusion and use of health technology.
    Drummond MF
    Health Policy; 1987 Jun; 7(3):309-24. PubMed ID: 10312123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating evaluations of new health technologies.
    Sisk JE
    Pharmacoeconomics; 1993 Jun; 3(6):511-2. PubMed ID: 10147130
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of economic appraisal in health technology assessment: the Australian case.
    Smith CS; Hailey D; Drummond M
    Soc Sci Med; 1994 Jun; 38(12):1653-62. PubMed ID: 8047924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to choose health technologies to be assessed by HTA? A review of criteria for priority setting.
    Specchia ML; Favale M; Di Nardo F; Rotundo G; Favaretti C; Ricciardi W; de Waure C;
    Epidemiol Prev; 2015; 39(4 Suppl 1):39-44. PubMed ID: 26499414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Handling time in economic evaluation studies.
    Permsuwan U; Guntawongwan K; Buddhawongsa P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S50-8. PubMed ID: 24964699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost escalation in health-care technology--possible solutions.
    Járos GG; Boonzaier DA
    S Afr Med J; 1993 Jun; 83(6):420-2. PubMed ID: 8211460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.